Literature DB >> 9328197

Incidence and mortality of neuroblastoma in Canada compared with other childhood cancers.

R N Gao1, I G Levy, W G Woods, B A Coombs, L A Gaudette, G B Hill.   

Abstract

The incidence and mortality of neuroblastoma was reviewed in the general context of childhood cancer in Canada for the periods 1982-86 and 1987-91. This was done to complement the preliminary work of the Quebec Neuroblastoma Screening Project that is studying the impact of screening North American infants for the preclinical detection of neuroblastoma on population-based mortality. Annual age-standardized incidence rates for all childhood cancer in Canada appear to have declined slightly (nonsignificantly) from 155.1 to 150.8 per million, between 1982-86 and 1987-91; the rates for neuroblastoma were stable between the two five-year periods (11.8 per million in 1982-86 and 11.4 per million in 1987-91). With respect to mortality, the age-standardized rates for childhood cancer in Canada have shown a declining trend between the first and second halves of the decade, from 43.4 to 34.7 per million, while the rates for neuroblastoma have not changed (4.4 and 4.2 per million). The age-specific distributions of incident cancers indicate that neuroblastoma accounts for the greatest proportion of all cancers in children less than one year of age. Similarly, neuroblastoma is the leading cause of cancer deaths in children aged one to four years. Theoretically, infants less than one year of age could benefit most from effective preventive interventions, treatment, and research.

Entities:  

Mesh:

Year:  1997        PMID: 9328197     DOI: 10.1023/a:1018483405637

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  4 in total

Review 1.  Nanomedicine as an innovative therapeutic strategy for pediatric cancer.

Authors:  Essa Mohd Aleassa; Malcolm Xing; Richard Keijzer
Journal:  Pediatr Surg Int       Date:  2015-02-18       Impact factor: 1.827

2.  Urinary catecholamine metabolites: Capillary gas chromatography method and experience with 12 cases of neuroblastoma.

Authors:  Sanja Grkovic; Rajko Nikolic; Maja Dordevic; Ljubomir Stojanov
Journal:  Indian J Clin Biochem       Date:  2005-07

3.  Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.

Authors:  Jungoh Ham; Carlotta Costa; Renata Sano; Timothy L Lochmann; Erin M Sennott; Neha U Patel; Anahita Dastur; Maria Gomez-Caraballo; Kateryna Krytska; Aaron N Hata; Konstantinos V Floros; Mark T Hughes; Charles T Jakubik; Daniel A R Heisey; Justin T Ferrell; Molly L Bristol; Ryan J March; Craig Yates; Mark A Hicks; Wataru Nakajima; Madhu Gowda; Brad E Windle; Mikhail G Dozmorov; Mathew J Garnett; Ultan McDermott; Hisashi Harada; Shirley M Taylor; Iain M Morgan; Cyril H Benes; Jeffrey A Engelman; Yael P Mossé; Anthony C Faber
Journal:  Cancer Cell       Date:  2016-02-08       Impact factor: 31.743

4.  Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma.

Authors:  Skye Balyasny; Sang Mee Lee; Ami V Desai; Samuel L Volchenboum; Arlene Naranjo; Julie R Park; Wendy B London; Susan L Cohn; Mark A Applebaum
Journal:  JAMA Netw Open       Date:  2021-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.